Loading…

YD Bio LimitedYDESCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties
Momentum neutral 52
Mkt cap
$344M
US dollars, full cap
Free float
20%
of shares outstanding
$/day
$524,013
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 6.6%
Hurdle
n/a
no reverse DCF
Close · USD$4.85
1D+2.5%
1W-21.1%
1M-16.9%
3M+1.3%
6M+6.6%
YTD-60.2%
1Y-54.8%
ATR %17.3%
Beta0.27
52w lowhigh69.2% off high

What YD Bio does

Employees: 15

YD Bio at a glance

Size YD Bio (YDES) is a United States Health Care company (Medical Specialties) with a market value of $344M, the 2968th largest of 3,085 United States companies the cockpit tracks. Shares closed at $4.85 on 18 Nov 2026.

Performance Over six months the shares gained 6.6%, against -15.3% for the median peer and -2.2% for the United States market (cap-weighted) — 4th highest of 20 in its peer set.

Growth Revenue grew 16.9% over the last twelve months (peer median +6.8%); the operating margin is -883.3% (peer median 9.4%).

Valuation It trades at 571.2× enterprise value to sales against a peer median of 4.2× (most expensive of 21).

Short interest Short interest is 0.3% of the free float (30 Oct 2026).

Relative performance

5010015021 May 202621 Aug 202618 Nov 2026YDES 107Peer median 85
Six months, rebased to 100: YD Bio against the median of its 20 peers (local-currency closes).

YD Bio financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenuen/a$596,817$510,360$0$0
Revenue growth—+17%———
Gross profitn/a-$42,150$50,621$0$0
EBITDAn/a-$5.06M-$1.36M-$2.07M-$2.32M
Net incomen/a-$8.31M-$1.41M-$2.55M$3.79M
Free cash flown/a-$8.04M-$1.30M-$2.02M-$3.02M
Capital expendituren/a$1.44M$2.91M$0$0
Total debtn/a$6,764$22,265$0$0

Quarterly statements and history in the cockpit →

YD Bio competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%-20%0%+20%EMBCCLTN688273377740301502VBSN300653197A6884686883383009421609SBSBWAY6748YDES6-month return →1-month return →
Up and to the right = strong over both horizons. YD Bio is the large dot.

Fundamentals: revenue growth against valuation

0%+20%0×200×400×EMBCCLTN688273377740301502VBSN197A6884683007531609CV5889BWAY6748YDESRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. YD Bio is the large dot.

YD Bio competitors and peer comparison

How YD Bio compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

YD Bio against its 20 peers (data as of 18 Nov 2026)
MeasureYDESPeer medianRank in peer set
1-month return-16.9%-8.8%2nd lowest of 21
6-month return+6.6%-15.3%4th highest of 20
Distance from 52-week high-69.2%-42.8%2nd lowest of 21
Revenue growth (TTM)+16.9%+6.8%5th highest of 21
Operating margin-883.3%9.4%lowest of 21
EV / Sales571.2×4.2×most expensive of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
YD Bio YDESUnited States$344M+7%+17%-883%571.2×n/an/a
Embecta EMBCUnited States$345M+99%-8%26%1.6×-19.9%-0.1%
COLTENE CLTN.SWSwitzerland$339M-7%-2%8%1.4×-0.3%-0.7%
Nanjing Medlander Medical Technology 688273.SSChina$337M-47%-12%8%4.2×35.3%+5.2%
BioNote 377740.KSSouth Korea$337M-14%+12%18%1.0×-15.0%-28.5%
Jiangsu Huayang Intelligent Equipment 301502.SZChina$336M-36%-5%2%4.9×34.3%+0.4%
IVF HARTMANN VBSN.SWSwitzerland$352M-2%+7%14%1.1×-12.7%-1.3%
Yantai Zhenghai Bio-Tech 300653.SZChina$354M-23%-8%17%5.4×18.4%+4.4%
Tauns Laboratories 197A.TJapan$327M-3%+7%29%4.4×n/an/a
Chemclin Diagnostics 688468.SSChina$327M-24%-10%4%6.4×15.8%-4.5%
Beijing Succeeder Technology 688338.SSChina$362M-18%-4%31%4.2×5.7%+3.4%
Jiangsu Apon Medical Technology 300753.SZChina$326M-34%-15%-10%6.9×20.0%-5.1%
Shenzhen Bioeasy Biotechnology 300942.SZChina$326M-27%+12%-2%7.4×n/an/a
Star Sports Medicine 1609.HKHong Kong$364M-73%+23%37%3.7×-13.1%+36.8%
Stratec SBS.DEGermany$365M+63%-6%4%1.8×19.1%+0.1%
CapsoVision CVUnited States$366M+5%+15%-213%24.8×n/an/a
Japan Eyewear 5889.TJapan$318M-5%+15%32%3.1×-9.4%+20.2%
Brainsway Ltd Sponsored ADR BWAYUnited States$373M-41%+32%14%4.8×24.9%+18.8%
Guangdong Transtek Medical Electronics 300562.SZChina$373M-15%+7%11%1.8×-4.2%-6.0%
ACRO Biomedical 6748.TWOTaiwan$377M+158%+45%-178%218.3×n/an/a
Medcaptain Medical Technology 2041.HKHong Kong$378Mn/a+19%2%1.5×17.1%+18.1%

Questions

Which companies are YD Bio's closest peers?
The cockpit's peer set: Embecta (EMBC), COLTENE (CLTN.SW), Nanjing Medlander Medical Technology (688273.SS), BioNote (377740.KS), Jiangsu Huayang Intelligent Equipment (301502.SZ), IVF HARTMANN (VBSN.SW), Yantai Zhenghai Bio-Tech (300653.SZ), Tauns Laboratories (197A.T).
Is YD Bio expensive compared with its peers?
On ev / sales it trades at 571.2× against a peer median of 4.2×, most expensive of 21 in its peer set.
How has YD Bio stock performed?
Over six months to 18 Nov 2026 the shares returned +6.6% against -15.3% for the median peer; over one year -54.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.